2 results
Approved WMOWill not start
The primary objective of this study is to assess tolerance and efficacy of 12 weeks BP1.3656 (30 µg or 60 µg OD versus placebo) to reduce alcohol consumption in alcohol dependent patients.
Approved WMORecruiting
Study CA001-050 is a Phase 2 randomized, open label, multicenter clinical study designed to assess the safety and tolerability, of treatment with MS-986012 in combination with chemotherapy (carboplatin and etoposide) and nivolumab when administered…